Pacific Biosciences of California (PACB) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Pacific Biosciences of California (US:PACB), trading at 1.48. In 2025, Pacific Biosciences of California generated $160.00 Million in revenue and -$113.92 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Pacific Biosciences of California is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 1.48
- Recent Revenue (2025): $160.00 Million
- Free Cash Flow (2025): -$113.92 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.